Risk and outcomes of COVID-19 in patients with multiple sclerosis

Irene Moreno-Torres; Virginia Meca  Lallana; Lucienne  Costa-Frossard; Celia  Oreja-Guevara; Clara  Aguirre; Elda María Alba  Suárez; Mayra Gómez  Moreno; Laura Borrega  Canelo; Julia Sabín  Muñoz; Yolanda  Aladro; Alba  Cárcamo; Elena Rodríguez  García; Juan Pablo  Cuello; Enric  Monreal; Susana  Sainz de la Maza; Fernando Pérez Parra Pérez Parra; Francisco  Valenzuela Rojas; Carlos  López de Silanes de Miguel; Ignacio  Casanova; Maria Luisa  Martínez Gines; Rosario  Blasco; Aida Orviz  García; Luisa María  Villar-Guimerans; Guillermo  Fernández-Dono; Victor Elvira; Carmen  Santiuste; Mercedes  Espiño; José Manuel  García Domínguez

doi:10.1111/ene.14990

Risk and outcomes of COVID-19 in patients with multiple sclerosis

Irene Moreno-Torres, Virginia Meca Lallana, Lucienne Costa-Frossard, Celia Oreja-Guevara, Clara Aguirre, Elda María Alba Suárez, Mayra Gómez Moreno, Laura Borrega Canelo, Julia Sabín Muñoz, Yolanda Aladro, Alba Cárcamo, Elena Rodríguez García, Juan Pablo Cuello, Enric Monreal , Susana Sainz de la Maza, Fernando Pérez Parra Pérez Parra, Francisco Valenzuela Rojas, Carlos López de Silanes de Miguel, Ignacio Casanova, Maria Luisa Martínez GinesRosario Blasco , Aida Orviz García, Luisa María Villar-Guimerans, Guillermo Fernández-Dono, Victor Elvira, Carmen Santiuste, Mercedes Espiño, José Manuel García Domínguez

School of Mathematics

Research output: Contribution to journal › Article › peer-review

Abstract

Background and purpose: Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS-CoV-2 infection and COVID-19-related outcomes in patients with MS, and compared these with the general population.

Methods: A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit admission, and death in patients with MS and COVID-19. National government outcomes and seroprevalence data were used for comparison. The study was conducted at 14 specialist MS treatment centers in Madrid, Spain, between February and May 2020.

Results: Two-hundred nineteen patients were included in the registry, 51 of whom were hospitalized with COVID-19. The mean age ± standard deviation was 45.3 ± 12.4 years, and the mean duration of MS was 11.9 ± 8.9 years. The infection incidence rate was lower in patients with MS than the general population (adjusted incidence rate ratio = 0.78, 95% confidence interval [CI] = 0.70-0.80), but hospitalization rates were higher (relative risk = 5.03, 95% CI = 3.76-6.62). Disease severity was generally low, with only one admission to an intensive care unit and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease-modifying treatment and hospitalization risk.

Original language	English
Pages (from-to)	3712-3721
Number of pages	26
Journal	European Journal of Neurology
Volume	28
Issue number	11
Early online date	21 Jun 2021
DOIs	https://doi.org/10.1111/ene.14990
Publication status	Published - 30 Nov 2021

Access to Document

10.1111/ene.14990

Risk and outcomes of COVID-19 in patients with multiple sclerosisAccepted author manuscript, 302 KB

Cite this

Moreno-Torres, I., Lallana, V. M., Costa-Frossard, L., Oreja-Guevara, C., Aguirre, C., Suárez, E. M. A., Moreno, M. G., Canelo, L. B., Muñoz, J. S., Aladro, Y., Cárcamo, A., García, E. R., Cuello, J. P., Monreal , E., Sainz de la Maza, S., Pérez Parra, F. P. P., Valenzuela Rojas, F., López de Silanes de Miguel, C., Casanova, I., ... García Domínguez , J. M. (2021). Risk and outcomes of COVID-19 in patients with multiple sclerosis. European Journal of Neurology, 28(11), 3712-3721. https://doi.org/10.1111/ene.14990

@article{5c78a1b611af46d2b88558869838c58a,

title = "Risk and outcomes of COVID-19 in patients with multiple sclerosis",

abstract = " Background and purpose: Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS-CoV-2 infection and COVID-19-related outcomes in patients with MS, and compared these with the general population.Methods: A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit admission, and death in patients with MS and COVID-19. National government outcomes and seroprevalence data were used for comparison. The study was conducted at 14 specialist MS treatment centers in Madrid, Spain, between February and May 2020.Results: Two-hundred nineteen patients were included in the registry, 51 of whom were hospitalized with COVID-19. The mean age ± standard deviation was 45.3 ± 12.4 years, and the mean duration of MS was 11.9 ± 8.9 years. The infection incidence rate was lower in patients with MS than the general population (adjusted incidence rate ratio = 0.78, 95% confidence interval [CI] = 0.70-0.80), but hospitalization rates were higher (relative risk = 5.03, 95% CI = 3.76-6.62). Disease severity was generally low, with only one admission to an intensive care unit and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease-modifying treatment and hospitalization risk. ",

author = "Irene Moreno-Torres and Lallana, {Virginia Meca} and Lucienne Costa-Frossard and Celia Oreja-Guevara and Clara Aguirre and Su{\'a}rez, {Elda Mar{\'i}a Alba} and Moreno, {Mayra G{\'o}mez} and Canelo, {Laura Borrega} and Mu{\~n}oz, {Julia Sab{\'i}n} and Yolanda Aladro and Alba C{\'a}rcamo and Garc{\'i}a, {Elena Rodr{\'i}guez} and Cuello, {Juan Pablo} and Enric Monreal and {Sainz de la Maza}, Susana and {P{\'e}rez Parra}, {Fernando P{\'e}rez Parra} and {Valenzuela Rojas}, Francisco and {L{\'o}pez de Silanes de Miguel}, Carlos and Ignacio Casanova and {Mart{\'i}nez Gines}, {Maria Luisa} and Rosario Blasco and Garc{\'i}a, {Aida Orviz} and Villar-Guimerans, {Luisa Mar{\'i}a} and Guillermo Fern{\'a}ndez-Dono and Victor Elvira and Carmen Santiuste and Mercedes Espi{\~n}o and {Garc{\'i}a Dom{\'i}nguez}, {Jos{\'e} Manuel}",

year = "2021",

month = nov,

day = "30",

doi = "10.1111/ene.14990",

language = "English",

volume = "28",

pages = "3712--3721",

journal = "European Journal of Neurology",

issn = "1351-5101",

publisher = "Wiley-Blackwell",

number = "11",

}

Moreno-Torres, I, Lallana, VM, Costa-Frossard, L, Oreja-Guevara, C, Aguirre, C, Suárez, EMA, Moreno, MG, Canelo, LB, Muñoz, JS, Aladro, Y, Cárcamo, A, García, ER, Cuello, JP, Monreal , E, Sainz de la Maza, S, Pérez Parra, FPP, Valenzuela Rojas, F, López de Silanes de Miguel, C, Casanova, I, Martínez Gines, ML, Blasco , R, García, AO, Villar-Guimerans, LM, Fernández-Dono, G, Elvira, V, Santiuste, C, Espiño, M & García Domínguez , JM 2021, 'Risk and outcomes of COVID-19 in patients with multiple sclerosis', European Journal of Neurology, vol. 28, no. 11, pp. 3712-3721. https://doi.org/10.1111/ene.14990

TY - JOUR

T1 - Risk and outcomes of COVID-19 in patients with multiple sclerosis

AU - Moreno-Torres, Irene

AU - Lallana, Virginia Meca

AU - Costa-Frossard, Lucienne

AU - Oreja-Guevara, Celia

AU - Aguirre, Clara

AU - Suárez, Elda María Alba

AU - Moreno, Mayra Gómez

AU - Canelo, Laura Borrega

AU - Muñoz, Julia Sabín

AU - Aladro, Yolanda

AU - Cárcamo, Alba

AU - García, Elena Rodríguez

AU - Cuello, Juan Pablo

AU - Monreal , Enric

AU - Sainz de la Maza, Susana

AU - Pérez Parra, Fernando Pérez Parra

AU - Valenzuela Rojas, Francisco

AU - López de Silanes de Miguel, Carlos

AU - Casanova, Ignacio

AU - Martínez Gines, Maria Luisa

AU - Blasco , Rosario

AU - García, Aida Orviz

AU - Villar-Guimerans, Luisa María

AU - Fernández-Dono, Guillermo

AU - Elvira, Victor

AU - Santiuste, Carmen

AU - Espiño, Mercedes

AU - García Domínguez , José Manuel

PY - 2021/11/30

Y1 - 2021/11/30

N2 - Background and purpose: Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS-CoV-2 infection and COVID-19-related outcomes in patients with MS, and compared these with the general population.Methods: A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit admission, and death in patients with MS and COVID-19. National government outcomes and seroprevalence data were used for comparison. The study was conducted at 14 specialist MS treatment centers in Madrid, Spain, between February and May 2020.Results: Two-hundred nineteen patients were included in the registry, 51 of whom were hospitalized with COVID-19. The mean age ± standard deviation was 45.3 ± 12.4 years, and the mean duration of MS was 11.9 ± 8.9 years. The infection incidence rate was lower in patients with MS than the general population (adjusted incidence rate ratio = 0.78, 95% confidence interval [CI] = 0.70-0.80), but hospitalization rates were higher (relative risk = 5.03, 95% CI = 3.76-6.62). Disease severity was generally low, with only one admission to an intensive care unit and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease-modifying treatment and hospitalization risk.

AB - Background and purpose: Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS-CoV-2 infection and COVID-19-related outcomes in patients with MS, and compared these with the general population.Methods: A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit admission, and death in patients with MS and COVID-19. National government outcomes and seroprevalence data were used for comparison. The study was conducted at 14 specialist MS treatment centers in Madrid, Spain, between February and May 2020.Results: Two-hundred nineteen patients were included in the registry, 51 of whom were hospitalized with COVID-19. The mean age ± standard deviation was 45.3 ± 12.4 years, and the mean duration of MS was 11.9 ± 8.9 years. The infection incidence rate was lower in patients with MS than the general population (adjusted incidence rate ratio = 0.78, 95% confidence interval [CI] = 0.70-0.80), but hospitalization rates were higher (relative risk = 5.03, 95% CI = 3.76-6.62). Disease severity was generally low, with only one admission to an intensive care unit and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease-modifying treatment and hospitalization risk.

U2 - 10.1111/ene.14990

DO - 10.1111/ene.14990

M3 - Article

SN - 1351-5101

VL - 28

SP - 3712

EP - 3721

JO - European Journal of Neurology

JF - European Journal of Neurology

IS - 11

ER -

Risk and outcomes of COVID-19 in patients with multiple sclerosis

Abstract

Access to Document

Fingerprint

Cite this